NDA 021823 · Warner Chilcott
Actonel With Calcium (Copackaged)
Calcium Carbonate, Risedronate Sodium · Oral
DiscontinuedLast checked: Nov 20, 2026Latest source record: Apr 8, 2015 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2005
Aug 12, 2005
Approved uses
1
Original approval plus efficacy supplements
Registered trials
596
144 Phase 3, 25 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 12, 2005 Original approval · Type 4 - New Combination LabelOther Important Information from FDALetter
1 products under this application
- ACTONEL WITH CALCIUM (COPACKAGED) · CALCIUM CARBONATE EQ 500MG BASE; RISEDRONATE SODIUM 35MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, ORAL · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Carbonate" as an intervention, any sponsor and status, largest first.
- A Study of MK-0822 in Postmenopausal Women With Osteoporosis to Assess Fracture Risk (MK-0822-018)Pivotal-lookingTerminated
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT00529373 · 16,071 participants · Start Sep 13, 2007 · Primary completion Nov 14, 2012
Drug: Odanacatib; Placebo for Odanacatib · For: Postmenopausal Osteoporosis
- Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLyPivotal-lookingRecruiting
Children's Oncology GroupResearch network
NCT03959085 · 5,951 participants (planned) · Start Oct 31, 2019 · Primary completion Mar 31, 2032
Drug: Blinatumomab; Calaspargase Pegol and 14 more · For: B Acute Lymphoblastic Leukemia; B Lymphoblastic Lymphoma; Central Nervous System Leukemia and 2 more
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 231 sites in all
- SAINT: Safe Induction of Labor TrialPivotal-lookingRecruiting
Oslo University HospitalAcademic, hospital or other
NCT05719467 · 3,000 participants (planned) · Start Jan 3, 2023 · Primary completion Jan 31, 2025
Drug: Buscopan 20 MG/ML Injectable Solution; Sodium bicarbonate and 2 more · For: Labor Complication; Induced; Birth; Pregnancy Related
Sites: Lørenskog, Norway; Oslo, Norway; Stavanger, Norway · 5 sites in all
- Vitamin D/Calcium Polyp Prevention StudyPivotal-lookingCompleted
Dartmouth-Hitchcock Medical CenterAcademic, hospital or other
NCT00153816 · 2,813 participants · Start Jul 2004 · Primary completion Oct 2013
Drug: Calcium Carbonate; Vitamin D3 and 1 more · For: Colorectal Cancer; Polyps; Adenomas
Sites: Los Angeles, California; Denver, Colorado; Atlanta, Georgia · 11 sites in all
ShireTakeda (TAK)
NCT00160121 · 2,500 participants · Start Jan 10, 2005 · Primary completion Dec 13, 2005
Drug: Lanthanum carbonate · For: Kidney Failure, Chronic
- Outcome Study of Lanthanum Carbonate Compared With Calcium Carbonate in Hemodialysis Patients : Landmark StudyPivotal-lookingCompleted
Translational Research Center for Medical Innovation, Kobe, Hyogo, JapanAcademic, hospital or other
NCT01578200 · 2,309 participants · Start Dec 24, 2011 · Primary completion Mar 25, 2019
Drug: Lanthanum Carbonate; Calcium Carbonate · For: Hemodialysis; Hyperphosphatemia
Sites: Shinagawa, Japan
- Sodium Bicarbonate in Cardiopulmonary ResuscitationPivotal-lookingStatus unknown
Rambam Health Care CampusAcademic, hospital or other
NCT01377337 · 2,130 participants (planned) · Start Dec 2011 · Primary completion Dec 2013
Drug: sodium bicarbonate · For: Sudden Cardiac Arrest
Sites: Haifa, Israel; Tel Aviv, Israel
- Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)Pivotal-lookingNot yet recruiting
Children's Oncology GroupResearch network
NCT07072585 · 1,708 participants (planned) · Start Aug 28, 2026 · Primary completion Sep 1, 2035
Drug: Bortezomib; Calaspargase Pegol and 16 more · For: Stage II T Lymphoblastic Leukemia/Lymphoma; Stage III T Lymphoblastic Leukemia/Lymphoma; Stage IV T Lymphoblastic Leukemia/Lymphoma and 2 more
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Systematic literature review and Bayesian network meta-analysis of episodic cluster headache drugs.
Pompilio G, Migliore A, Integlia D · Eur Rev Med Pharmacol Sci 2021 · Network Meta-Analysis, Systematic Review
- Meta-analysis of calcium bioavailability: a comparison of calcium citrate with calcium carbonate.
Sakhaee K, Bhuket T, Adams-Huet B, et al. · Am J Ther 1999 · Comparative Study, Meta-Analysis
- Systematic review and meta-analysis: value of venous blood gas in the diagnosis of acute exacerbation of chronic obstructive pulmonary disease in Emergency Department.
Sheng F, Chen L, Lin H, et al. · Ann Palliat Med 2022 · Meta-Analysis, Systematic Review
- Effect of lanthanum carbonate on the progression of coronary artery calcification in hemodialysis patients: A meta-analysis of randomized controlled trials.
Xu JP, Zeng RX, Liao PD, et al. · Hemodial Int 2022 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Calcium Citrate Versus Calcium Carbonate in the Management of Chronic Hypoparathyroidism: A Randomized, Double-Blind, Crossover Clinical Trial.
Naciu AM, Tabacco G, Bilezikian JP, et al. · J Bone Miner Res 2022 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Evaluation of the cost-utility of phosphate binders as a treatment option for hyperphosphatemia in chronic kidney disease patients: a systematic review and meta-analysis of the economic evaluations.
Chaiyakittisopon K, Pattanaprateep O, Ruenroengbun N, et al. · Eur J Health Econ 2021 · Meta-Analysis, Systematic Review
Sponsor: Warner Chilcott
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.